Comparative Pharmacology
Head-to-head clinical analysis: ALBAMYCIN versus R P MYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBAMYCIN versus R P MYCIN.
ALBAMYCIN vs R-P MYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
None Documented
None Documented
3.5-4.5 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment, requiring dose adjustment.
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Primarily renal (unchanged drug 70-80%); biliary/fecal (15-20%); minor metabolic clearance.
Renal (60-80% unchanged), biliary/fecal (15-20%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic